Marinus Pharmaceuticals (NASDAQ:MRNS) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Marinus Pharmaceuticals (NASDAQ:MRNS) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02, reports. The business had revenue of $8.54 million during the quarter, compared to the consensus estimate of $8.95 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 446.48%.

Marinus Pharmaceuticals Stock Down 12.4 %

MRNS opened at $0.30 on Thursday. The stock has a market cap of $16.65 million, a price-to-earnings ratio of -0.12 and a beta of 1.26. Marinus Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $11.26. The business has a 50 day moving average of $1.28 and a 200-day moving average of $1.34.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Hussman Strategic Advisors Inc. boosted its position in Marinus Pharmaceuticals by 14.3% during the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 10,500 shares during the period. AQR Capital Management LLC lifted its stake in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 12,934 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $28,000. SG Americas Securities LLC acquired a new position in Marinus Pharmaceuticals in the 2nd quarter valued at about $34,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Marinus Pharmaceuticals in the 1st quarter valued at about $384,000. Institutional investors own 98.80% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on MRNS. StockNews.com began coverage on shares of Marinus Pharmaceuticals in a report on Sunday. They issued a “hold” rating on the stock. HC Wainwright reiterated a “neutral” rating and issued a $2.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Nine analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $4.79.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.